Institut Jules Bordet
Hospital
Location:
Bruxelles / Brüssel / Brussels,
Belgium (BE)
ISNI: 000000010684291X
ROR: https://ror.org/05e8s8534
Show on Map:
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) (2017)
Loibl S, De La Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, et al.
Journal article
Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations (2017)
Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, Van Der Geest L, Lemmens V, et al.
Journal article
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group (2016)
Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, et al.
Journal article
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014)
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, et al.
Journal article
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer (2014)
Loibl S, Von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, et al.
Journal article